trastuzumab rezetecan

mAbexperimentalADC

Clinical trial activity

7 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
7
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2025 (NCT07047755)

Timeline

2020s

  1. Jan 1, 2025

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Payload
rezetecan

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07309770Phase 2Dec 18, 2025Fudan University
NCT07129018Phase 2Nov 30, 2025Eastern Hepatobiliary Surgery Hospital, Huazhong University of Science and Technology
NCT07241793Phase 2Nov 20, 2025Guangzhou Medical University, Huazhong University of Science and Technology, Kunming Medical University, Sun Yat-Sen University
NCT07203729Phase 2Nov 1, 2025Chinese Academy of Medical Sciences
NCT07179939Phase 2Sep 10, 2025Fudan University, Hengrui Therapeutics, Inc., People's Liberation Army of China
NCT07100600Phase 2Aug 30, 2025Henan Medical University
NCT07047755Phase 2Jul 1, 2025Henan Medical University
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Fudan UniversityAcademic/Hospital2212025
Henan Medical UniversityAcademic/Hospital2212025
Huazhong University of Science and TechnologyAcademic/Hospital2112025
Chinese Academy of Medical SciencesAcademic/Hospital1112025
Eastern Hepatobiliary Surgery HospitalAcademic/Hospital1012025
Guangzhou Medical UniversityAcademic/Hospital1012025
Hengrui Therapeutics, Inc.For profit1012025
Kunming Medical UniversityAcademic/Hospital1012025
People's Liberation Army of ChinaGovernment1012025
Sun Yat-Sen UniversityAcademic/Hospital1112025
10 organizations
Page 1 / 1